【摘要】 目的 评价奥曲肽治疗晚期原发性肝癌的疗效和不良反应。方法 对20例住院的原发性肝癌患者给予善宁(Octreotide)100 μg/次皮下注射,2次/d,用至疗效有进展证据时停药。结果 客观疗效:在第1、2次评价期内,全组无完全缓解,2例部分缓解,5例好转,8例稳定,5例进展。20例TTP为(3.0±1.5)个月,中位生存期为6个月,3例已存活24个月;临床受益疗效:疼痛缓解阳性率为50%,生存质量提高占70%,行为状态阳性率为60%,体质量变化阳性率为40%。该治疗方案仅有轻度的毒副反应,主要表现为恶心、呕吐,WHOⅠ级3例、Ⅱ级3例、Ⅲ级1例;其次是腹泻WHOⅠ级6例、Ⅱ级2例。结论 奥曲肽用于治疗晚期原发性肝癌安全、有效、毒性低。更多还原

【Abstract】 Objective: To discuss the effects and untoward reactions of octreotide in the treatment of late primary hepatic cancer. Methods: 20 PHC patients with octreotide 100μg. ql2 h were treated till the disease progresses. Results: During the first and second periods, there was no complete remission, but 2 cases of partial remission, 5 cases of minimal remission, 8 cases of stable disease, and 5 cases of progression disease. In this group, the TTP of the 20 cases was (3±1.5) months, median survival was 24 months, clinical effects, pain remission rate was 50%,the rate of improved quality of life was 70%,the positive rate of behavior state was 60%,the positive rate of weight change was 40%.The side effects of the therapy were rare, and there were only minimal reactions, the main performance was nausea and vom-it, WHO Ⅰ grade was 3 cases, WHO Ⅱ grade was 3 cases, WHO Ⅲ grade was 1 case, then it was diarrhea, WHO Ⅰ grade was 6 cases, WHOⅡ grade was 2 cases. Conclusions: The treatment PHC with octreoride is efficient, safe and side effects are rare.更多还原